News|Articles|March 4, 2025
Optimizing next-generation sequencing for precision oncology trials
Author(s)Thermo Fisher Scientific
This article explores how optimizing next-generation sequencing (NGS) in oncology trials can enhance patient identification, boosts efficiency, and enables diverse recruitment.
Trending on PharmExec
1
FDA Pannel Votes to Loosen Restrictions for Four Peptides
2
Pharmaceutical Executive Daily: FDA Votes to Reduce Restrictions on Four Peptides
3
President Trump Announces Phased Generic Drug Tariff Plan: Report
4
Retatrutide Delivers Up to 22.6% Weight Loss in Two New Phase III Trials
5